Latest Regulatory Approval News

Mount Gibson Iron reported a significant net loss for FY25 amid weaker iron ore prices but is pivoting towards gold with a major acquisition in the Northern Territory.

Mount Gibson Iron Limited reported a substantial net loss for FY2025 amid iron ore price drops and operational challenges, while announcing a strategic acquisition in the gold sector.

The Environmental Group Limited (EGL) reported a robust FY25 with revenue climbing 13.9% to $111.9 million and underlying EBITDA up 9.9%, driven by strategic acquisitions and advances in PFAS technology. The company projects further EBITDA growth of 15-20% in FY26, underpinned by expanding recurring revenue streams.

Yancoal Australia Ltd reported a sharp 61% drop in net profit for the first half of 2025, hit by falling coal prices and supply chain disruptions despite a 15% rise in production. The company declared a fully franked interim dividend and is advancing key asset deals and growth projects.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Wide Open Agriculture has launched a pre-feasibility study for a large-scale lupin protein facility in Western Australia, aiming to establish a new global food category and reduce production costs. This move marks a pivotal step toward commercial scale and global leadership in sustainable plant-based proteins.

Tombador Iron Limited is set to transform itself by acquiring GoviEx Uranium, creating a new ASX-listed uranium company focused on Zambia’s Muntanga Project. This deal includes a significant capital raise and board overhaul, aiming for a November 2025 completion.

Amplitude Energy has delivered record production and earnings in FY25, driven by operational improvements and a strategic joint venture for the East Coast Supply Project.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

Resouro Strategic Metals launches a CAD 2 million private placement to fund engineering work advancing its Tiros project in Brazil, marking a key step toward a Preliminary Economic Assessment.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.